Effect of p53 status on tumor response to antiangiogenic therapy - PubMed (original) (raw)

. 2002 Feb 22;295(5559):1526-8.

doi: 10.1126/science.1068327.

Affiliations

• PMID: 11859195
• DOI: 10.1126/science.1068327

Effect of p53 status on tumor response to antiangiogenic therapy

Joanne L Yu et al. Science. 2002.

Abstract

The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that might reduce their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy. Here, we report that mice bearing tumors derived from p53(-/-) HCT116 human colorectal cancer cells were less responsive to antiangiogenic combination therapy than mice bearing isogenic p53(+/+) tumors. Thus, although antiangiogenic therapy targets genetically stable endothelial cells in the tumor vasculature, genetic alterations that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.

PubMed Disclaimer

Comment in

• Cancer research. Obstacle for promising cancer therapy.
  Marx J. Marx J. Science. 2002 Feb 22;295(5559):1444. doi: 10.1126/science.295.5559.1444a. Science. 2002. PMID: 11859164 No abstract available.
• Antiangiogenic therapy and p53.
  Hammond EM, Giaccia AJ. Hammond EM, et al. Science. 2002 Jul 26;297(5581):471; discussion 471. doi: 10.1126/science.297.5581.471a. Science. 2002. PMID: 12142499 No abstract available.
• Antiangiogenic therapy and p53.
  Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS. Browder T, et al. Science. 2002 Jul 26;297(5581):471; discussion 471. Science. 2002. PMID: 12143876 No abstract available.

Similar articles

• Antiangiogenic therapy and p53.
  Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS. Browder T, et al. Science. 2002 Jul 26;297(5581):471; discussion 471. Science. 2002. PMID: 12143876 No abstract available.
• Cancer research. Obstacle for promising cancer therapy.
  Marx J. Marx J. Science. 2002 Feb 22;295(5559):1444. doi: 10.1126/science.295.5559.1444a. Science. 2002. PMID: 11859164 No abstract available.
• Antiangiogenic therapy and p53.
  Hammond EM, Giaccia AJ. Hammond EM, et al. Science. 2002 Jul 26;297(5581):471; discussion 471. doi: 10.1126/science.297.5581.471a. Science. 2002. PMID: 12142499 No abstract available.
• Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
  Wachsberger P, Burd R, Dicker AP. Wachsberger P, et al. Clin Cancer Res. 2003 Jun;9(6):1957-71. Clin Cancer Res. 2003. PMID: 12796357 Review.
• A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.
  Yu JL, Coomber BL, Kerbel RS. Yu JL, et al. Differentiation. 2002 Dec;70(9-10):599-609. doi: 10.1046/j.1432-0436.2002.700913.x. Differentiation. 2002. PMID: 12492501 Review.

Cited by

• Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.
  Kumar S, Mokhtari RB, Oliveira ID, Islam S, Toledo SR, Yeger H, Baruchel S. Kumar S, et al. Transl Oncol. 2013 Aug 1;6(4):493-503. doi: 10.1593/tlo.13286. Print 2013 Aug. Transl Oncol. 2013. PMID: 23908692 Free PMC article.
• Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
  Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Patel SA, et al. Clin Cancer Res. 2023 Jan 4;29(1):30-39. doi: 10.1158/1078-0432.CCR-22-1366. Clin Cancer Res. 2023. PMID: 35969170 Free PMC article. Review.
• Mechanisms of resistance to anti-angiogenic treatments.
  Pezzella F. Pezzella F. Cancer Drug Resist. 2019 Sep 19;2(3):595-607. doi: 10.20517/cdr.2019.39. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582580 Free PMC article. Review.
• Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
  Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Piha-Paul SA, et al. Oncotarget. 2014 Apr 15;5(7):1846-55. doi: 10.18632/oncotarget.1834. Oncotarget. 2014. PMID: 24742900 Free PMC article. Clinical Trial.
• Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.
  Chen Y, Henson ES, Xiao W, Shome E, Azad MB, Burton TR, Queau M, Sathya A, Eisenstat DD, Gibson SB. Chen Y, et al. Cancer Biol Ther. 2016 Jun 2;17(6):604-13. doi: 10.1080/15384047.2015.1095399. Epub 2015 Oct 15. Cancer Biol Ther. 2016. PMID: 26467103 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal